Lombard Medical touts small Altura study
Eighteen patients (75%) were discharged by the 24-hour mark and there were no deaths within 30 days, Lombard said. The incidence of immediate or delayed access-related complications was zero and there was a 100% rate of technical success and freedom from Type I/III endoleaks, the company said.
“The significance of the low contrast doses, low screen and procedure times and radiation dose reduction, already demonstrates some of the key benefits the new Altura system offers, even taking into account that this data includes the learning curve across 2 units. It has the potential to be a game-changer for EVAR as we have already been able to perform two-thirds of our Altura cases as ‘day-case’ procedures,” Murray said in prepared remarks.
“We are extremely pleased with our early experience using Altura, the learning curve is rapid and it has quickly become the ‘go to’ endograft in our vascular unit,” added University Hospital South Manchester’s Dr. Steve Richardson.
“Altura clearly offers unique benefits to physicians and patients and significantly enhances the treatment of patients with standard AAA anatomy. Its unique features including an ultra-low profile 14F delivery system, the elimination of the unpredictable procedure step of ‘stent graft gate cannulation’ and retrograde iliac deployment all add up to a simpler, quicker, predictable and safer procedure with optimum outcomes,” Lombard CEO Simon Hubbert said.